longbridge

Lyell Immunopharma

LYEL
----

All Shareholders

Shareholder Type

  • Institutions36.56%
  • VC/PE firms25.66%
  • Private companies17.56%
  • Public and others12.96%
  • Individuals & Insiders7.26%

Major Shareholders

Major Shareholders Latest
Shareholder
Arch Venture Partners, L.P.
13.25%3.25M0.67%+0
Innovative Cellular Therapeutics Holdings Limited
11.32%2.77M0.89%-82.52K
Gates Frontier, LLC
6.24%1.53M0.31%+0
Explore Investments LLC
6.24%1.53M0.31%+0
GSK Equity Investments, Limited
6.17%1.51M0.31%+0
Antonis Indianos
5.82%1.43M0.29%+0
Mwg Management Ltd.
4.11%1.01M0.21%+0
Vanguard Capital Management, LLC
3.59%879.87K0.14%+74.79K
Apoletto Limited
3.08%754.70K0.16%+0
BlackRock, Inc.
2.96%724.34K2.13%+532.52K
Decheng Capital LLC
2.82%692.05K0.14%+0
Almitas Capital LLC
2.37%581.41K0.10%+3.60K
Foresite Capital Management, LLC
1.94%476.39K3.53%-801.09K
Millennium Management LLC
1.50%367.47K0.47%-91.43K
Opaleye Management Inc.
1.40%344.03K1.06%+264.93K
venBio LLC
1.38%337.70K0.07%+0
Geode Capital Management, LLC
1.27%310.64K0.55%+143.66K
GV Management Company, LLC
1.20%293.26K0.06%+0
Richard KlausnerFounder & Executive Chairman
0.78%190.56K0.72%-158.00K
State Street Investment Management
0.76%185.32K0.45%+112.80K
© 2026 Longbridge｜Terms of ServicePrivacy Policy